摘要
目的探讨干扰素α和恩替卡韦治疗HBeAg阳性慢性乙型肝炎的临床疗效。方法回顾性分析慢性乙型肝炎患者97例的临床资料,其中48例患者采用普通干扰素治疗为普通干扰素组,49例采用恩替卡韦治疗为恩替卡韦组。治疗48周比较HBe Ag转阴率、HBV DNA低于检测下限率以及ALT恢复正常率。结果治疗48周,两组HBV DNA低于检测值下限率、ALT恢复正常率、HBeAg转阴率比较差异无统计学意义(P>0.05)。普通干扰素α组HBeAg血清学转换率显著高于恩替卡韦组(P<0.01)。普通干扰素α组HBeAg血清学转换患者HBeAg显著低于未血清学转换的患者(P<0.01)。结论干扰素α和恩替卡韦治疗慢性乙型肝炎各有优缺点,在临床中应根据患者具体情况选择最佳治疗方案。
Objective To discuss clinical efficacy of interferon-α and entecavir in treatment of HBeAg-positive chronic hepatitis B. Methods Clinical data of 97 cases with HBeAg-positive chronic hepatitis B were retrospectively analyzed. Forty-eight cases of group of interferon-αwere treated by interferon-α, and 49 cases of group of entecavir were treated by entecavir. After 48 weeks, rates of HBeAg loss, HBV DNA〈1000 copies/mL, normalization of ALT of two groups were compared.Results After treatment for 48 weeks, HBV DNA〈1000 copies/mL, HBeAg loss and normalization of ALT rates of two groups showed no significant differences（P〉0.05）. HBeAg seroconversion rate of interferon-α group was higher than entecavir group（P〈0.01）. In interferon-α group, HBeAg level of patients with HBeAg seroconversion was lower than no HBeAg seroconversion patients（P〈0.01）. ConclusionInterferon-α and entecavir in treatment of chronic hepatitis B show different advantages and disadvantages. In clinical practice, doctors should choose the best treatment options based on the specific circumstances of the patients.
出处
《中国医药科学》
2015年第7期99-101,共3页
China Medicine And Pharmacy
